FindTrial
Sign In

A Phase II, single-arm, open-label, long-term safety rollover trial of oral brigimadlin in patients with solid tumours

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-514177-21-00
Acronym
1403-0032
Enrollment
24
Registered
2024-10-23
Start date
2024-12-02
Completion date
Unknown
Last updated
2025-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid tumours

Brief summary

Occurrence of treatment-emergent AEs according to CTCAE Version 5.0 during the entire treatment period

Interventions

DRUGBI 907828

Sponsors

Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Occurrence of treatment-emergent AEs according to CTCAE Version 5.0 during the entire treatment period—

Countries

Belgium, Czechia, Denmark, France, Germany, Hungary, Italy, Norway, Poland, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026